The thyroid pathway represents a complex interaction of different glands for thyroid hormone synthesis. Thyrotropin releasing hormone is synthesized in the hypothalamus and regulates thyrotropin stimulating hormone gene expression in the pituitary gland. In order to understand the complexity of the thyroid pathways, and using experimental data retrieved from the biomedical literature (e.g., NCBI, HuGE Navigator, Protein Data Bank, and KEGG), we constructed a metabolic map of the thyroid hormone pathway at a molecular level and analyzed it topologically. A total of five hub nodes were predicted in regards to the transcription thyroid receptor (TR), cAMP response element-binding protein (CREB), signal transducer and activator of transcription 3 (STAT 3), nuclear factor kappa-light-chain-enhancer of activated B cells (NFkB), and activator protein 1 (AP-1) as being potentially important in study of thyroid disorders and as novel putative therapeutic drug targets. Notably, the thyroid receptor is a highly connected hub node and currently used as a therapeutic target in hypothyroidism. Our analysis represents the first comprehensive description of the thyroid pathway, which pertains to understanding the function of the protein and gene interaction networks. The findings from this study are therefore informative for pathophysiology and rational therapeutics of thyroid disorders.
Get full access to this article
View all access options for this article.
References
1.
AbelED, AhimaRS, BoersME, ElmquistJK, WondisfordFE. 2001. Critical role for thyroid hormone receptor beta 2 in the regulation of paraventricular thyrotropin-releasing hormone neurons. J Clin Invest, 107:1017–1023.
2.
Arnaud-LopezL, UsalaG, CeresiniGet al.2008. Phosphodiesterase 8B gene variants are associated with serum TSH levels and thyroid function. Am J Hum Genet, 82:1270–1280.
BarabásiAL. 2009. Scale-free networks: A decade and beyond. Science, 325:412–413.
6.
BoykinC, ZhangG, ChenYHet al.2011. CucurbitacinIIa: A novel class of anti-cancer drug inducing non-reversible actin aggregation and inhibiting survivin independent of JAK2/STAT3 phosphorylation. Br J Cancer, 104:781–789.
7.
BressonD, RebuffatSA, Péraldi-RouxS. 2005. Localization of the immunodominant region on human thyroid peroxidase in autoimmune thyroid diseases: An update. J Autoimmune Dis, 2:2.
8.
ButcherEC, BergEL, KunkelEJ. 2004. Systems biology in drug discovery. Nat Biotechnol, 22:1253–1259.
9.
CalzoneL, GelayA, ZinovyevA, RadvanyiF, BarillotE. 2008. A comprehensive modular map of molecular interactions in RB/E2F pathway. Mol Syst Biol, 4:173.
10.
CameronAC, WindmeijerFAG. 1997. An R-squared measure of goodness of fit for some common nonlinear regression models. J Econometrics, 77:329–342.
11.
ChenD, FrezzaM, SchmittS, KanwarJ, DouQP. 2011. Bortezomib as the first proteasome inhibitor anticancer drug: Current status and future perspectives. Curr Cancer Drug Targets, 11:239–253.
12.
ChoYY, ShonHS, YoonHD. 2005. Management of a pregnant patient with Graves' disease complicated by propylthiouracil induced agranulocytosis. Korean J Intern Med, 20:335–338.
DemirE, CaryMP, PaleySet al.2010. The BioPAX community standard for pathway data sharing. Nat Biotechnol, 28:935–942.
15.
FeketeC, LechanRM. 2007. Negative feedback regulation of hypophysiotropic thyrotropin-releasing hormone (TRH) synthesizing neurons: Role of neuronal afferents and type 2 deiodinase. Front Neuroendocrinol, 28:97–114.
16.
FunahashiA, TanimuraN, MorohashiM, KitanoH. 2003. CellDesigner: A process diagram editor for gene-regulatory and biochemical networks. Biosilico1, 159–162.
17.
GargA, AggarwalBB. 2002. Nuclear transcription factor-kappa B as a target for cancer drug development. Leukemia, 16:1053–1068.
18.
GuptaMK, MisraK. 2013. Modeling and simulation analysis of propylthiouracil (PTU), an anti-thyroid drug on thyroid peroxidase (TPO), thyroid stimulating hormone receptor (TSHR) and sodium iodide symporter (NIS) based on systems biology approach. Netw Model Anal Health Inform Bioinforma 10.1007/s13721-013-0023-0.
19.
GuptaMK, SinghDB, RathSK, MisraK. 2012. Metabolic modeling and simulation analysis of thyroid disorder pathway. J Comput Sci Syst Biol, 5:52–61.
20.
HaydenMS, GhoshS. 2004. Signaling to NF-kappa B. Genes Dev, 18:2195–2224.
21.
HuckaM, FinneyA, BornsteinBJet al.2004. Evolving a lingua franca and associated software infrastructure for computational systems biology: The Systems Biology Markup Language (SBML) project. Systems Biology, 1:41–53.
22.
HussainAR, AhmedSO, AhmedMet al.2012. Cross-talk between NFkB and the PI3-kinase/AKT pathway can be targeted in primary effusion lymphoma (PEL) cell lines for efficient apoptosis. PLoS One, 7:e39945.
KallóI, MohácsikP, VidaBet al.2012. A novel pathway regulates thyroid hormone availability in rat and human hypothalamic neurosecretory neurons. PLoS One, 7:e37860.
25.
KellDB. 2006. System biology, metabolic modeling and metabolomics in drug discovery and development. Drug Discov Today, 11:1085–1092.
26.
KenneyJW, PooleRL, AdoffMD, LogueSF, GouldTJ. 2012. Learning and nicotine interact to increase CREB phosphorylation at the jnk1 promoter in the hippocampus. PLoS One, 7:e39939.
27.
KöhrleJ. 2005. Selenium and the control of thyroid hormone metabolism. Thyroid, 15:841–853.
28.
LawrenceT. 2009. The nuclear factor NF-kappaB pathway in inflammation. Cold Spring Harb Perspect Biol, 1:a001651.
29.
Le NovèreN, HuckaM, MiHet al.2009. The Systems biology graphical notation. Nat Biotechnol, 27:735–741.
30.
LinN, UrabeK, MoroiYet al.2006. Overexpression of phosphorylated-STAT3 and phosphorylated-ERK protein in dermatofibrosarcoma protuberans. Eur J Dermatol, 16:262–265.
31.
LiuY, LiC, LinJ. 2010. STAT3 as a therapeutic target for glioblastoma. Anticancer Agents Med Chem, 10:512–519.
32.
MirandaP, GiráldezT, de la PeñaPet al.2005. Specificity of TRH receptor coupling to G-proteins for regulation of ERG K+ channels in GH3 rat anterior pituitary cells. J Physiol, 566:717–736.
33.
MondulAM, WeinsteinSJ, BosworthT, RemaleyAT, VirtamoJ, AlbanesD. 2012. Circulating thyroxine, thyroid-stimulating hormone, and hypothyroid status and the risk of prostate cancer. PLoS One, 7:e47730.
34.
MongaV, MeenaCL, KaurN, JainR. 2008. Chemistry and biology of thyrotropin-releasing hormone (TRH) and its analogs. Curr Med Chem, 15:2718–2733.
MuellerS, KleinauG, JaeschkeH, PaschkeR, KrauseG. 2008. Extended hormone binding site of the human thyroid stimulating hormone receptor: Distinctive acidic residues in the hinge region are involved in bovine thyroid stimulating hormone binding and receptor activation. J Biol Chem, 283:18048–18055.
37.
NakashimaT, TaurogA, RiescoG. 1978. Mechanism of action of thioureylene antithyroid drugs: Factors affecting intrathyroidal metabolism of propylthiouracil and methimazole in rats. Endocrinology, 103:2187–2197.
38.
NanjappaV, RajuR, MuthusamyBet al.2011. A comprehensive curated reaction map of leptin signaling pathway. J Proteomics Bioinform, 4:184–189.
39.
NeumannS, EliseevaE, McCoyJGet al.2011. A new small-molecule antagonist inhibits Graves' disease antibody activation of the TSH receptor. J Clin Endocrinol Metab, 96:548–554.
40.
NeumannS, PopeA, Geras-RaakaE, RaakaBM, BahnRS, GershengornMC. 2012. A drug-like antagonist inhibits thyrotropin receptor-mediated stimulation of cAMP production in Graves' orbital fibroblasts. Thyroid, 22:839–843
41.
NeumannS, RaakaBM, GershengornMC. 2009. Human TSH receptor ligands as pharmacological probes with potential clinical application. Expert Rev Endocrinol Metab, 4:669.
42.
NewmanMEJ, WattsDJ, BarabásiA. 2006. The Structure and Dynamics of Networks. Princeton University Press: Princeton.
43.
NillniEA, VasletC, HarrisM, HollenbergA, BjørbakC, FlierJS. 2000. Leptin regulates prothyrotropin-releasing hormone biosynthesis. Evidence for direct and indirect pathways. J Biol Chem, 275:36124–36133.
44.
NillniEA. 2010. Regulation of the hypothalamic thyrotropin releasing hormone (TRH) neuron by neuronal and peripheral inputs. Front Neuroendocrinol, 31:134–156.
45.
PerelloM, StuartRC, NillniEA. 2006. The role of intra cerebroventricular administration of leptin in the stimulation of prothyrotropin releasing hormone neurons in the hypothalamic paraventricular nucleus. Endocrinology, 147:3296–3306.
46.
PorcuE, MediciM, PistisGet al.2013. A meta-analysis of thyroid-related traits reveals novel loci and gender-specific differences in the regulation of thyroid function. PLoS Genet, 9:e1003266.
47.
RawalR, TeumerA, VölzkeHet al.2012. Meta-analysis of two genome-wide association studies identifies four genetic loci associated with thyroid function. Hum Mol Genet, 21:3275–3282.
48.
Riesco-EizaguirreG, SantistebanP. 2006. A perspective view of sodium iodide symporter research and its clinical implications. Eur J Endocrinol, 155:495–512.
RufJ, CarayonP. 2006. Structural and functional aspects of thyroid peroxidase. Arch Biochem Biophys, 445:269–277.
51.
SatoH, MinagawaM, SasakiNet al.2011. Comparison of methimazole and propylthiouracil in the management of children and adolescents with Graves' disease: Efficacy and adverse reactions during initial treatment and long-term outcome. J Pediatr Endocrinol Metab, 24:257–263.
52.
SchapiraM, RaakaBM, DasSet al.2003. Discovery of diverse thyroid hormone receptor antagonists by high-throughput docking. Proc Natl Acad Sci USA, 100:7354–7359.
53.
ShannonP, MarkielA, OzierOet al.2003. Cytoscape: A software environment for integrated models of biomolecular interaction networks. Genome Res, 13:2498–2504.
54.
SimmD, PfarrN, PohlenzJ, PrawittD, DörrHG. 2009. Two novel mutations in the human thyroid peroxidase (TPO) gene: Genetics and clinical findings in four children. Acta Paediatr, 98:1057–1061.
TajimaT, TsubakiJ, FujiedaK. 2005. Two novel mutations in the thyroid peroxidase gene with goitrous hypothyroidism. Endocr J, 52:643–645.
59.
TegederI, NiederbergerE, IsrarEet al.2001. Inhibition of NF-kappaB and AP-1 activation by R- and S-flurbiprofen. FASEB J, 15:595–597.
60.
ToyodaN, KapteinE, BerryMJ, HarneyJW, LarsenPR, VisserTJ. 1997. Structure-activity relationships for thyroid hormone deiodination by mammalian type I iodothyroninedeiodinases. Endocrinology, 138:213–219.
61.
VallabhajosyulaRR, ChakravartiD, LutfealiS, RayA, RavalA. 2009. Identifying hubs in protein interaction networks. PLoS One, 4:e5344.
62.
VanderpumpMP. 2011. The epidemiology of thyroid disease. Br Med Bull, 99:39–51.
WonerowP, NeumannS, GudermannT, PaschkeR. 2001. Thyrotropin receptor mutations as a tool to understand thyrotropin receptor action. J Mol Med (Berl), 79:707–721.
65.
WuCC, SheteS, ChenWV, PengB, LeeAT, MaJ, GregersenPK, AmosC.I. 2009. Detection of disease-associated deletions in case-control studies using SNP genotypes with application to rheumatoid arthritis. Hum Genet, 126:303–315.
66.
WuG, ZhuL, DentJE, NardiniC. 2010. A comprehensive molecular interaction map for rheumatoid arthritis. PLoS One, 5:e10137.
67.
YenPM. 2001. Physiological and molecular basis of thyroid hormone action. Physiol Rev, 81:1097–1142.
68.
YuW, WulfA, LiuT, KhouryMJ, GwinnM. 2008. Gene Prospector: An evidence gateway for evaluating potential susceptibility genes and interacting risk factors for human diseases. BMC Bioinformatics, 9:528.
69.
ZhanX, DesiderioDM. 2010. Signaling pathway networks mined from human pituitary adenoma proteomics data. BMC Med Genomics, 3:13.
70.
ZinovyevA, ViaraE, CalzoneL, BarillotE. 2008. BiNoM: A Cytoscape plugin for manipulating and analyzing biological networks. Bioinformatics, 24:876–877.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
